Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms

被引:0
作者
Deng Bo [1 ]
Jia Liqun [1 ]
Tan Huangying [1 ]
Lou Yanni [1 ]
Li Xue [1 ]
Li Yuan [1 ]
Yu Lili [1 ]
机构
[1] China Japan Friendship Hosp, Integrat Oncol Dept, Beijing 100029, Peoples R China
关键词
UGT1A1; enzyme; Diarrhea; Irinotecan; Shengjiangxiexin decoction; COLORECTAL-CANCER PATIENTS; INDUCED DIARRHEA; OXALIPLATIN; UGT1A;
D O I
暂无
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
OBJECTIVE: To evaluate the efficacy of Shengjiangxiexin decoction (SXD), prepared with a formula from Traditional Chinese Medicine (TCM), in reducing irinotecan-induced hematological and gastrointestinal toxicities in patients with UDP-glucuronosyltransferase (UGT)1A1*28 and UGT1A1*6 polymorphisms. METHODS: This clinical trial included 115 patients receiving irinotecan combined with 5-fluorouracil plus 1-leucovorin (FOLFIRI) treatment. All patients consented to UGT1A1*28 and *6 gene polymorphism detection prior to chemotherapy. SXD were administered from 1 day prior to chemotherapy to 6 day post chemotherapy. Chemotherapy induced adverse reactions (neutropenia, diarrhea, nausea, vomiting, anorexia and infection) were recorded, and short-term effect of chemotherapy was evaluated regularly." RESULTS: A total of 50 patients had *1/*1 wild genotype, 58 patients had single allele variants with genotype *1/*6 or *1/*28, and 7 patients had two alleles variants with genotype *6/*6, *28/*28 or *61* 28. In *1/*6 or *1/*28 patients (high risk group),.9 patients (15.5%) developed I II grade diarrhea and no patient developed severe diarrhea; neutropenia occurred in 19 patients (32.8%) and only 3 patients (8.6%) developed sever neutropenia. There were no significant differences in any toxic effects (neutropenia, diarrhea, nausea, vomiting, anorexia or infection) between *6 or *28 variant patients (high risk group) and wild type patients. No sever toxicity was found in high risk two alleles variants patients (*6/*6, *6/*28 or *28/*28). No significant differences were observed between UGT1A1*6/*28 polymorphisms and clinical response of chemotherapy. CONCLUSION: SXD could significantly reduce irinotecan-induced hematological and gastrointestinal toxicities in UGT1A1*28 or *6 variant patients (high risk group), while this treatment didn't affect clinical response of chemotherapy. (C) 2017 JTCM. All rights reserved.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 24 条
[1]  
Ando Y, 2000, CANCER RES, V60, P6921
[2]  
Cancer Therapy Evaluation Program, 2006, Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0
[3]   UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians [J].
Cheng, Lei ;
Li, Ming ;
Hu, Jing ;
Ren, Wei ;
Xie, Li ;
Sun, Zhan-Peng ;
Liu, Bao-Rui ;
Xu, Gen-Xing ;
Dong, Xiao-Liang ;
Qian, Xiao-Ping .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) :551-560
[4]  
Deng HY, 2006, ZHONG RI YOU HAO YI, V20, P344
[5]  
Deng HY, 2007, ZHONG GUO MIAN YI XU, V23, P620
[6]   UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan [J].
Ferraldeschi, Robert ;
Minchell, Laura J. ;
Roberts, Stephen A. ;
Tobi, Simon ;
Hadfield, Kristen D. ;
Blackhall, Fiona H. ;
Mullamitha, Saifee ;
Wilson, Gregory ;
Valle, Juan ;
Saunders, Mark ;
Newman, William G. .
PHARMACOGENOMICS, 2009, 10 (05) :733-739
[7]   Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) [J].
Gagné, JF ;
Montminy, V ;
Belanger, P ;
Journault, K ;
Gaucher, G ;
Guillemette, C .
MOLECULAR PHARMACOLOGY, 2002, 62 (03) :608-617
[8]   Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients [J].
Gao, Jing ;
Zhou, Jun ;
Li, Yanyan ;
Peng, Zhi ;
Li, Yilin ;
Wang, Xicheng ;
Shen, Lin .
MEDICAL ONCOLOGY, 2013, 30 (03)
[9]   UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients [J].
Gao, Jing ;
Zhou, Jun ;
Li, Yanyan ;
Lu, Ming ;
Jia, Ru ;
Shen, Lin .
MEDICAL ONCOLOGY, 2013, 30 (03)
[10]   The Jujube (Ziziphus Jujuba Mill.) Fruit: A Review of Current Knowledge of Fruit Composition and Health Benefits [J].
Gao, Qing-Han ;
Wu, Chun-Sen ;
Wang, Min .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2013, 61 (14) :3351-3363